Traws Pharma Inc (TRAW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Traws Pharma Inc (TRAW) has a cash flow conversion efficiency ratio of 0.485x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.58 Million) by net assets ($-5.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Traws Pharma Inc (TRAW) balance sheet quality index to measure how much of total assets are equity-financed.
Traws Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Traws Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TRAW cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Traws Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Traws Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KESSELRUN RESOURCES LTD
F:CMG
|
N/A |
|
Pool Advista Indonesia Tbk
JK:POOL
|
0.022x |
|
DB ENERGY S.A. ZY -10
F:0CJ
|
-0.032x |
|
Straits Inter Logistics Bhd
KLSE:0080
|
-0.018x |
|
Credit Intelligence Ltd
AU:CI1
|
0.066x |
|
Apptech Corp
NASDAQ:APCX
|
-0.455x |
|
Seafarms Group Ltd
AU:SFG
|
2.045x |
|
REFINED METALS CORP. O.N.
F:CWA0
|
-0.684x |
Annual Cash Flow Conversion Efficiency for Traws Pharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Traws Pharma Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Traws Pharma Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-629.00K | $-18.18 Million | 28.911x | +2969.46% |
| 2024-12-31 | $-31.63 Million | $-29.79 Million | 0.942x | +156.06% |
| 2023-12-31 | $10.67 Million | $-17.93 Million | -1.680x | -191.93% |
| 2022-12-31 | $28.31 Million | $-16.29 Million | -0.576x | -36.22% |
| 2021-12-31 | $46.12 Million | $-19.49 Million | -0.423x | +88.69% |
| 2020-12-31 | $6.17 Million | $-23.07 Million | -3.737x | -107.62% |
| 2019-12-31 | $11.57 Million | $-20.83 Million | -1.800x | +57.28% |
| 2018-12-31 | $5.39 Million | $-22.70 Million | -4.213x | -292.10% |
| 2017-12-31 | $-10.86 Million | $-23.82 Million | 2.193x | +171.11% |
| 2016-12-31 | $5.13 Million | $-15.81 Million | -3.084x | -6.77% |
| 2015-12-31 | $10.84 Million | $-31.31 Million | -2.889x | -18.37% |
| 2014-12-31 | $23.62 Million | $-57.65 Million | -2.440x | -221.63% |
| 2013-12-31 | $80.90 Million | $-61.38 Million | -0.759x | -7255.60% |
| 2012-12-31 | $-158.31 Million | $1.63 Million | -0.010x | -110.08% |
| 2011-12-31 | $-138.42 Million | $-14.17 Million | 0.102x | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more